Dr. Claudio Schteingart joined Ferring on July 1996. He is the Vice President, Science & Technology-Research and his responsibilities include evaluation of new technologies for the discovery and development of novel peptide therapeutics. In addition, he also provides guidance to drug discovery programs and support to drug candidates in development. Dr. Schteingart’s Ferring career started with a position as a research chemist where he participated in the discovery of the peptidic GnRH antagonist degarelix, launched in 2009, and five other peptidic drug candidates in various stages of clinical development for women’s health, critical care medicine, and gastroenterology. Dr. Schteingart received a Ph.D. in Chemistry at the University of Buenos Aires, Argentina. After postdoctoral studies in the Department of Chemistry at the University of California, San Diego, he moved to the Department of Medicine where he carried out research in the chemistry, physiology, metabolism, and physicochemical properties of biliary components and lipids.